Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.66 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.66 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.48 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.48 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.47 |
| ▸ | F2R | P25116 | 4/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1532653 | 0.98 | ITGB3 (0.64) | ITGB3ITGA2BFAAHSLC6A1GABRA5 | |
| SCHEMBL5751261 | 0.94 | ITGB3 (0.69) | ITGB3ITGA2BFAAHSLC6A1GABRA5 | |
| SCHEMBL5501220 | 0.93 | ITGB3 (0.59) | ITGB3ITGA2BFAAHSLC6A1GABRA5 | |
| SCHEMBL17440475 | 0.92 | ITGB3 (0.67) | ITGB3ITGA2BFAAHSLC6A1GABRA5 | |
| Hydrochloric Acid SCHEMBL29119874 | 0.90 | ITGB3 (0.65) | ITGB3ITGA2BFAAHSLC6A1GABRA5 | |
| SCHEMBL5494841 | 0.88 | SLC6A1 (0.60) | ITGB3ITGA2BFAAHSLC6A1GABRA5 | |
| SCHEMBL954535 | 0.87 | ITGB3 (0.56) | ITGB3ITGA2BSLC6A1GABRA5GABRB2 | |
| SCHEMBL23909396 | 0.86 | ITGB3 (0.60) | ITGB3ITGA2BSLC6A1GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL3159636 | 0.85 | ITGB3 (0.54) | ITGB3ITGA2BSLC6A1GABRA5GABRB2 | |
| SCHEMBL29193847 | 0.84 | KDM5A (0.53) | ITGB3ITGA2BSLC6A1GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | claimed |
| EP-3939972-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | claimed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | claimed |
| EP-3545978-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2021-09-08 | — | — | EP | claimed |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | claimed |
| EP-3545978-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | claimed |
| EP-3300746-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2019-05-15 | — | — | EP | claimed |
| US-20190134237-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | claimed |
| CN-105025933-B | Triazine Radiopharmaceuticals and Radioimaging Agents | 分子制药洞察公司 | 2019-03-26 | — | — | CN | claimed |
| US-10201624-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | claimed |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | claimed |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-03 | — | — | US | claimed |
| EP-1828240-B1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NAT RECH SCIENT (FR) | 2009-07-29 | — | — | EP | claimed |
| US-7410949-B2 | Genetically engineered truncated analogs of significantly lower-molecular-weight and having equal or better potency, pharmacokinetic properties and pharmacological properties as existing Y2R agonists; also pegylated analogs; treating obesity; dietetics; metabolic disorders | HOFFMANN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | claimed |
| JP-2008527017-A | — | — | 2008-07-24 | — | — | JP | claimed |
| CN-101107266-A | Peptides having neuropeptide-2 receptor (Y2R) agonist activity | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | claimed |
| EP-1844070-A1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| WO-2006077035-A9 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2006-10-26 | — | — | WO | claimed |
| WO-2006077035-A1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | claimed |
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | DANHO WALEED | 2006-07-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | ITGB3 2256/4885ITGA2B 1367/4885FAAH 3627/4885 |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CD40, CD40LG, TNFSF10 | ITGB3 1229/4885ITGA2B 1360/4885FAAH 4564/4885 |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | ITGB3 2256/4885ITGA2B 1367/4885FAAH 3627/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | ITGB3 2256/4885ITGA2B 1367/4885FAAH 3627/4885 |
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | NPY2R, NPY1R, NPY4R | ITGB3 3703/4885ITGA2B 3345/4885FAAH 900/4885 |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | TNFRSF1A, TNFRSF9, CD40 | ITGB3 1120/4885ITGA2B 757/4885FAAH 3509/4885 |
| US-10201624-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA5, PSMA2, PSMA1 | ITGB3 3306/4885ITGA2B 2378/4885FAAH 2573/4885 |
| US-20190134237-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | ITGB3 2256/4885ITGA2B 1367/4885FAAH 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.